companies / ngmbio-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-07 json
| total_raised | 122,000,000122.0M | ○ |
|---|---|---|
| founded | 2008 | |
| hq | South San Francisco CA | |
| industry | unknown | |
| stage | series-a |
NGM Bio is a clinical-stage biopharmaceutical developing antibody therapeutics targeting GDF15 signalling. It serves patients suffering from hyperemesis gravidarum and cancer cachexia, two conditions with severely limited treatment options. Its lead program NGM120 is the only GDF15/GFRAL antagonist antibody in clinical development across both indications.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-07-01 | series-a | 122,000,000122.0M | null | ○ |
Vercel, Next.js, React, Webpack
| fact | status | src |
|---|---|---|
| Series A, $122.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |